FDA's Pazdur Won't Become Oncology Bureaucrat: 'My Presence Will Be Felt'
This article was originally published in The Pink Sheet Daily
Richard Pazdur is stepping aside from FDA's Office of Hematology and Oncology Products to head the agency's newly created Oncology Center of Excellence, but he expects to still run twice-weekly group meetings at OHOP.
You may also be interested in...
The 21st Century Cures Act regulatory reform provisions amount to a lot of little things: tweaks to encourage ongoing activities rather than bold departures at a time when the overall regulatory climate is good for innovators. But the law could also be the start of something bigger – a more formal division within the US FDA between oncology and everything else.
Vice President’s Cancer Moonshot project could provide final thrust for '21st Century Cures' bill in the lame duck Congressional session after election.
Compendia are often critical to reimbursement for oncology sponsors, but University of North Carolina researchers argue in JAMA the system needs to be revamped.